The role of allopurinol in metabolic dysfunction-associated steatotic liver disease: A randomized clinical trial

Key Points

• Allopurinol treatment is linked to improvements in liver enzymes, indicating potential benefits for steatotic liver disease.
• Participants receiving allopurinol showed a significant reduction in oxidative stress markers after treatment.
• Randomized clinical trial methodology allows robust evaluation of allopurinol's efficacy in this patient population.
• These findings support potential therapeutic strategies for managing metabolic dysfunction-related liver conditions.